Millions of people are living with long COVID—a condition that lingers for months or years after infection, bringing fatigue, brain fog, dizziness, and heart palpitations that won't quit. But here's what's shifted: researchers at Mass General Brigham have just identified eight distinct patterns in how the condition progresses, a finding that could reshape how doctors support patients and what treatments might actually work.
The research, part of a large initiative called RECOVER, tracked adults months and years after their COVID infection. What emerged was clear: long COVID isn't one disease. It's at least eight different ones, each unfolding on its own timeline.
What the data shows
About 1 in 10 people who had COVID developed long COVID symptoms that persisted beyond three months. Of those who did, 81% were still dealing with symptoms a year later—some better, some worse, some stuck in a frustrating cycle of good days and crashes.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxWomen and people who'd been hospitalized with acute COVID faced higher odds of developing the most severe, persistent form. That matters because it helps clinicians know who needs the most intensive support from day one.
But the real insight lies in the eight trajectories the team mapped. Some patients hit a plateau of mild symptoms and stay there. Others start mild and gradually improve. Some experience waves of severity. A small group developed symptoms months after their initial infection—the kind of delayed onset that catches people off guard. And yes, some got persistently worse.
Bruce Levy, the senior researcher, frames this plainly: "This study addresses an urgent need to define the differing long COVID trajectories." Translation: doctors have been treating long COVID like it's one thing, when they've actually been treating eight different things. No wonder outcomes vary so wildly.
The implications ripple outward. If you know a patient is likely on the "gradually improving" trajectory, you can set realistic expectations and focus on maintaining function. If someone's heading toward persistent severity, you can marshal resources earlier. Researchers can now look for the biological markers—the blood tests, the immune signatures—that predict which path a person will take. That's the bridge between pattern and treatment.
Tanayott Thaweethai, the first author, notes that this variability is actually useful: "The variability we identified will enable future studies to evaluate risk factors and biomarkers that could explain why patients vary in time of recovery, and help identify potential therapeutic targets." In other words, the messiness of long COVID—the fact that it looks different in every person—is now a map instead of just chaos.
The work was funded by the National Institutes of Health and represents the kind of foundational science that doesn't make headlines but quietly changes clinical practice. Next comes the harder part: figuring out which interventions help which trajectory, and why.
